{
    "2020-09-08": [
        [
            {
                "time": "",
                "original_text": "首 次 海 外 并 购 遭 遇 巨 大 商 誉 减 值  汤 臣 倍 健 为 何 继 续 押 宝 “ 益 生 菌 ” ？  资 产 异 常",
                "features": {
                    "keywords": [
                        "海外并购",
                        "商誉减值",
                        "汤臣倍健",
                        "益生菌",
                        "资产异常"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "保健品",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "同 仁 堂 跨 界 有 点 “ 折 腾 ”",
                "features": {
                    "keywords": [
                        "同仁堂",
                        "跨界",
                        "折腾"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "中医药",
                        "多元化经营"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}